ProKidney Corp. (NASDAQ:PROK) Insider Sells $312,509.60 in Stock

ProKidney Corp. (NASDAQ:PROK - Get Free Report) insider Darin J. Weber sold 103,480 shares of the stock in a transaction that occurred on Tuesday, July 8th. The stock was sold at an average price of $3.02, for a total value of $312,509.60. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

ProKidney Stock Up 19.4%

NASDAQ PROK traded up $0.84 on Thursday, reaching $5.18. 73,053,515 shares of the stock traded hands, compared to its average volume of 3,208,249. The firm's fifty day simple moving average is $0.97 and its 200 day simple moving average is $1.16. The company has a market cap of $1.52 billion, a price-to-earnings ratio of -8.63 and a beta of 1.26. ProKidney Corp. has a 12 month low of $0.46 and a 12 month high of $7.13.

ProKidney (NASDAQ:PROK - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.03. The firm had revenue of $0.23 million for the quarter. As a group, equities research analysts forecast that ProKidney Corp. will post -0.57 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on PROK shares. Citigroup increased their price objective on ProKidney from $6.00 to $9.00 and gave the stock a "buy" rating in a report on Wednesday. Wall Street Zen raised ProKidney from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, Bank of America lowered ProKidney from a "neutral" rating to an "underperform" rating and decreased their price objective for the stock from $3.00 to $1.00 in a report on Monday, June 30th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. According to MarketBeat, ProKidney presently has a consensus rating of "Hold" and a consensus target price of $5.33.

Hedge Funds Weigh In On ProKidney

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its stake in ProKidney by 106.4% during the 1st quarter. AQR Capital Management LLC now owns 52,570 shares of the company's stock valued at $46,000 after purchasing an additional 27,098 shares in the last quarter. Nuveen LLC bought a new stake in shares of ProKidney during the 1st quarter worth $233,000. Deutsche Bank AG boosted its stake in shares of ProKidney by 49.4% during the 1st quarter. Deutsche Bank AG now owns 86,337 shares of the company's stock worth $76,000 after acquiring an additional 28,546 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of ProKidney by 8.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 825,647 shares of the company's stock worth $723,000 after acquiring an additional 65,860 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of ProKidney by 4.3% during the 1st quarter. Bank of New York Mellon Corp now owns 239,673 shares of the company's stock worth $210,000 after acquiring an additional 9,903 shares in the last quarter. 51.59% of the stock is owned by institutional investors.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.